SCHEMBL27218738

SCHEMBL27218738

Oc1cc(C(F)(F)F)nc(SCc2nc(-c3ccc4c(c3)OCO4)no2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 3/20 0.47
▸ THRB P10828 1/20 0.47
▸ MAPT P10636 3/20 0.47
▸ KDM4E B2RXH2 5/20 0.44
▸ ALDH1A1 P00352 5/20 0.44
▸ HPGD P15428 5/20 0.44
▸ GAA P10253 3/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ TP53 P04637 3/20 0.44
▸ L3MBTL1 Q9Y468 3/20 0.44
▸ CHRM2 P08172 1/20 0.43
▸ CHRM5 P08912 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218860 0.90 RAB9A (0.47) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL31494431 0.85 RAB9A (0.45) MAPTALDH1A1GAAPOLBTP53
SCHEMBL27218815 0.85 RAB9A (0.49) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL27218699 0.85 RAB9A (0.57) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL27218710 0.82 LMNA (0.46) MAPTALDH1A1GAAL3MBTL1CHRM2
SCHEMBL27218773 0.81 NPC1 (0.45) MAPTALDH1A1GAAPOLBTP53
SCHEMBL27218770 0.81 CHRM2 (0.45) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL31494450 0.80 MAPT (0.47) MAPTALDH1A1HPGDGAAL3MBTL1
SCHEMBL27218790 0.80 RAB9A (0.48) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL31494445 0.79 CHRM2 (0.44) MAPTKDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 RXFP1 106/4885THRB 252/4885MAPT 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback